1. Scrip
  2. >>Business
  3. >>Deals

Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D

 
• By Joseph Haas

Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.

Tech Transfer

Athenex, Inc.announced a licensing agreement on 9 November with the US National Cancer Institute (NCI) to expand its development capabilities for T-cell receptor (TCR)-based allogeneic natural killer T (NKT) cell and autologous T cell therapeutic products for the treatment of human cancers. Under the agreement, Athenex obtains worldwide rights to the development, manufacturing and commercialization of allogeneic NKT products engineered via viral and non-viral means, as well as autologous TCR products engineered via retrovirus and lentivirus-mediated gene transfer.

The TCRs licensed from NCI recognize antigens derived from mutations in p53, KRAS and EGFR genes shared among multiple patients and tumor types, the partners said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from Business